To demonstrate that a hypo-fractionated course of radiotherapy (ie. an accelerated radiotherapy course where fewer but larger doses of radiotherapy are given) is both safe and effective in the treatment of low-risk localized prostate cancer.

Inclusion Criteria:- Eligible patients will have clinical stage T1c through T2b, initial PSA level <10 and a biopsy Gleason score of 3+3 or 3+4 with fewer than 50% of biopsy cores involved.

• Patients who have had any form of prior curative treatment (surgery, radiotherapy, cryotherapy) will not be eligible. A prior course of hormone therapy of less than 3 months duration will be allowed.
• Adult men will be considered.
• No life expectancy restrictions will apply.
• Performance Status will not be considered.
• No requirements for organ or marrow function will be made
• Ability to understand and the willingness to sign a written informed consent document. Exclusion Criteria:- No prior prostate treatment will be allowed.
• The use of other concurrent Investigational Agents will not be allowed.
• No exclusion requirements due to co-morbid disease or incurrent illness.
• No requirements regarding history of allergic reactions.
• Pregnancy or nursing patients is not applicable (ie. patients are male).